Navigation Links
NIH report on intracranial stent points out need for upcoming large-scale clinical trial
Date:2/14/2008

LOS ANGELES (Feb. 13, 2008) A preliminary study funded by the National Institutes of Health found that a stent designed to open clogged arteries in the brain was successfully deployed in nearly all cases and significantly reduced arterial blockage in the short term. But data on the long-term benefit of the stent, compared to medical treatment alone, were inconclusive, prompting the upcoming launch of a large-scale randomized trial that is expected to provide definitive results.

The NIH Wingspan Registry collected statistics on 129 patients who had an intracranial artery narrowed by at least 70 percent and were experiencing recurrent strokes or transient ischemic attacks (TIAs or mini-strokes) despite being on anti-clotting medication. Treatment included use of the Wingspan intracranial stent developed by Boston Scientific. Seven centers in the United States participated in the trial, and results are published online in the journal Neurology.

Treatment options for stroke patients with severe blockages are extremely limited. As opposed to the situation in blocked heart arteries where options include angioplasty, stenting and surgical bypass, there is no surgical option for these blockages in the brain. This stent may be a major advance for patients with high-grade stenosis (arterial narrowing) who have a stroke or TIA. Previously they could just take medication and expect to have a high recurrent stroke rate, said neurosurgeon Michael J. Alexander, M.D., one of the articles authors and director of the Cedars-Sinai Neurovascular Center. Before coming to Cedars-Sinai Medical Center in 2007, Alexander was founder and director of the Neurovascular Center at Duke University, where he was one of the Wingspan study leaders.

The Wingspan trial followed another NIH-funded study comparing two blood-thinning medications commonly used to treat narrowing of intracranial arteries. The Warfarin-Aspirin Symptomatic Intracranial Disease Study (WASID) found that warfarin (commonly known by the brand name Coumadin) and aspirin provided similar stroke protection, but aspirin was associated with a lower risk of hemorrhage and related complications.

The WASID study also found that a patient who recently had a stroke or TIA and suffered a cranial artery blockage of 70 percent or higher had a 22 percent chance of having another stroke within the first year, regardless of which medication was used. While the objective of the WASID trial was to compare the two drugs, results of the medication study provide a baseline against which other therapies can be compared.

We know that patients with 70 percent to 99 percent stenosis and TIA or stroke within the previous 30 days are at highest risk of having another stroke, Alexander said. These are the patients who have the most to gain from stenting and are the ones we will target for enrollment in the randomized trial of stenting versus medical therapy.


'/>"/>

Contact: Sandy Van
sandy@prpacific.com
800-880-2397
Cedars-Sinai Medical Center
Source:Eurekalert

Related medicine news :

1. US Oncology to Report 2007 Fourth Quarter and Year-End Earnings Results
2. The Quantum Group Reports 4th Quarter and Year End Results for Fiscal Year 2007
3. Kaiser Foundation Health Plan and Hospitals Reports Fourth Quarter and Fiscal Year-End 2007 Financial Results
4. AtriCure Reports Fourth Quarter and Full Year 2007 Record Financial Results
5. Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69
6. AMERIGROUP Reports Q4 Net Income of $31.1 Million or $0.57 Per Diluted Share; Full-Year Net Income of $116.5 Million or $2.16 Per Diluted Share
7. Allscripts Reports Fourth Quarter 2007 Results
8. IRC Reports Claimed Medical Expenses for Auto Injury Claimants Far Outpace Inflation
9. UCI Medical Affiliates, Inc. Reports First Quarter Fiscal Year 2008 Results
10. SearchMedicas Second Quarterly Top Clinical Search Terms Report Reveals Top 25 Oncology, General Medicine and Psychiatry Search Terms Among Medical Professionals
11. The Female Health Company Reports 37% Revenue Growth and Record Profits for First Quarter of FY2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Come to ... Hotel, 4200 Jim Walter Blvd, for an educational and exciting 2-day program. , ... our staff hearing this before they approach patients” about the course entitled Ain't Misbehavin': ...
(Date:4/24/2017)... Calif. (PRWEB) , ... April 24, 2017 , ... Donna ... topics, but she has not found any of them to be very practical. She ... to slowly and easily make changes in their health. It prompted her in writing ...
(Date:4/24/2017)... ... April 24, 2017 , ... “Reflections of God’s Work”: an enlightening collection of ... is the creation of published author, Jerri Broglin, a survivor of great loss who ... this a great eye-opener for those searching for answers, as we are finding the ...
(Date:4/24/2017)... ... 24, 2017 , ... “The Saint with Trin, and Omega Station”: a triple ... the creation of published author, Chris Jackson. Chris Jackson grew up in Abilene, ... Dallas Independent School District teaching English. He is heavily involved in the youth group ...
(Date:4/24/2017)... ... April 24, 2017 , ... Life of Purpose Treatment is ... The event will be held at 7:30 pm on May 10th at the University ... Copeland of Sister Hazel, will support the UF Collegiate Recovery Community (UFCRC). The concert ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... -- Companion animal vaccines are ... such as canine, avian and feline. ... as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, ... Vaccines. Attenuated live vaccines are derived from disease-causing ... been weakend under laboratory conditions. Conjugate vaccines are ...
(Date:4/18/2017)... 18, 2017  Cardinal Health (NYSE: CAH ... 2017 earnings per share (EPS) guidance and providing a ... in conjunction with this morning,s announcement of the planned ... Nutritional Insufficiency businesses. Cardinal Health now believes ... be at the bottom of its previous guidance range ...
(Date:4/18/2017)... -- Astute Medical, Inc., developer of biomarkers for better healthcare, ... the 2017 National Kidney Foundation (NKF) Spring Clinical ... 22. Physicians will present data on two biomarkers, ... acute kidney injury (AKI) during the management of patients ... Elevated levels of TIMP-2 and IGFBP-7 have been shown ...
Breaking Medicine Technology: